Display & Selection Technologies

The Display & Selection Technologies unit supports the development of therapeutic antibodies and single domain antibodies. The unit will assist by isolating human antibodies from in-house constructed IP free phage libraries towards target proteins as suggested by the partner PI. It will be of critical importance that the partner PI has substantial knowledge and know-how of the target protein/biological system, either from a clinical or basic scientific perspective. The objective is to deliver a reasonable number of candidate clones for further in vivo characterization in collaboration with the partner PI.

Services

• Generation of well-characterized human antibodies for therapy
  • Selection and cloning of monoclonal, high-affinity human antibody fragments from IP free phage display libraries
  • Re-cloning, expression and purification of isolated antibodies as full-length format IgG molecules
  • Initial characterization of the isolated antibodies, including e.g. DNA/amino acid sequence, binding specificity and selectivity, affinity, stability, aggregation, epitope mapping
  • Assessment of function and biological potency of the antibodies using in vitro assays
• Collaborate in the design of relevant assays for biological potency of the antibodies, and in the design of proof-of-concept studies
• Consulting at the pre-project proposal stage with potential partner PIs on project design

Equipment

• Highly diverse IP free human antibody phage libraries
• Single domain antibody library is under construction
• Fully equipped pro- and eukaryotic cell culture laboratories
• Protein purification ÄKTA systems
• SPR Biacore 8K
• ELISA work station
• KingFisher Flex system
• iQue Plus flow cytometer
• NanoDSF Prometheus
• Isothermal titration calorimeter